Carregant...
Global Proteome Quantification for Discovering Imatinib-induced Perturbation of Multiple Biological Pathways in K562 Human Chronic Myeloid Leukemia Cells
Imatinib mesylate, currently marketed by Novartis as Gleevec in the US, has emerged as the leading compound to treat chronic phase of chronic myeloid leukemia (CML), through its inhibition of Bcr-Abl tyrosine kinase, and other cancers. However, resistance to imatinib develops frequently, particularl...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2974763/ https://ncbi.nlm.nih.gov/pubmed/20949922 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/pr100814y |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|